Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5490 - Precision medicine for patients with advanced biliary tract cancers: updated results from the prospective MOSCATO trial


09 Sep 2017


Poster display session


Translational Research;  Hepatobiliary Cancers


Loic Verlingue


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


L. Verlingue1, D. Malka2, A. Allorant3, C. Massard1, C. Ferté4, L. Lacroix5, E. Rouleau6, N. Auger7, J. Delahousse8, R. Sun9, T. de Baere10, L. Tselikas11, B. Ba12, J. Scoazec13, S. Michiels14, V. Boige15, M. Ducreux15, J. Soria1, A. Hollebecque1

Author affiliations

  • 1 Drug Development Department (ditep), Gustave Roussy, 94805 - Villejuif/FR
  • 2 Digestive Oncology, Institut de Cancérologie Gustave Roussy, 94800 - Villejuif/FR
  • 3 Biostatistics, Gustave Roussy, 94805 - Villejuif/FR
  • 4 Head And Neck, Gustave Roussy, 94805 - Villejuif/FR
  • 5 Bmo, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 6 Département De Biologie Et Pathologie Médicales, Gustave ROUSSY, 94805 - VILLEJUIF/FR
  • 7 Biology And Pathology Department, Gustave Roussy Cancer Campus Grand Paris, 94800 - Villejuif/FR
  • 8 Pharmacology, Institut de Cancérologie Gustave Roussy, 94800 - Villejuif/FR
  • 9 Radiotherapy Department, Radiomics Inserm U1030, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 10 Radiology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 11 Radiology, Gustave Roussy, 94805 - Villejuif/FR
  • 12 Radiology, Institut de Cancérologie Gustave Roussy, 94800 - Villejuif/FR
  • 13 Pathology, Gustave Roussy Institute, Villejuif/FR
  • 14 Service De Biostatistique Et D'epidémiologie, Gustave Roussy, 94800 - Villejuif/FR
  • 15 Gastrointestinal Unit , Institut Gustave Roussy, Villejuif/FR


Abstract 5490


Advanced biliary tract cancers (aBTCs) are heterogeneous diseases with a median overall survival (OS) < 1year. Platinum-based chemotherapy doublets are the frontline standard-of-care. Increasing evidence points out the strong addiction of aBTCs to druggable oncogenic alterations. We assessed the success rate and the clinical benefit of administering molecular targeted agents (MTAs) based on the molecular alterations found in patients with aBTCs.


Patients with aBTCs were prospectively enrolled in our prospective molecular screening program (MOSCATO 01). An on-purpose tumor biopsy was performed for each patient, followed by high-throughput molecular analysis. Patients were then guided to MTAs matching the molecular alterations. The primary endpoint was progression-free survival (PFS), with clinical benefit defined by a PFS ratio (PFS [MTA]/PFS [prior line]) >1.3.


From November 2011 to March 2016, among 1036 adult patients included in the MOSCATO-01 trial, 48 biopsy procedures were performed in 43 patients (4%) with aBTC (4 patients re-included, one 3 times).Thirty three patients (77%) had intrahepatic cholangiocarcinoma. Patients had failed a median of 2 previous lines (range, 1-5). Successful biopsy procedures and DNA extractions enabled molecular analysis in 38 samples (79%), and at least one molecular alteration was detected in 35 samples (71%). Following analysis, 25 patients could be orientated to an appropriate early clinical trial or accessible MTA (25/38, 66%), and 19 patients could be treated on the basis of molecular alterations (19/38, 50%). For the biology-driven treatment group, The PFS ratio was 1.52 [0.08, 7.1]. Six patients (32%) had an objective response (complete [CR] or partial [PR] response), 16 (84%) had a clinical benefit (stable disease+PR+CR), and 7 (37%) had a PFS≥6 months. This strategy led to a significant overall survival improvement compared to patients who were not treated according to their tumor molecular characterization (HR = 0.26 [95%CI, 0.10 − 0.67], p = 0.003).


With 25 patients out of 48 inclusions (52%) driven to a MTA, patients with aBTCs are ideal candidates for molecular profiling.

Clinical trial identification

MOSCATO (NCT01566019)

Legal entity responsible for the study

Jean Charles Soria




L. Verlingue: Consultant Adaptherapy. E. Rouleau: Board meeting for AstraZeneca, Roche. V. Boige: Consulted or advised for Merck Serono, Amgen, Sanofi-Aventis, Prestizia and Bayer; honoraria from Amgen, Merck Serono, Roche, Novartis and Bayer; research funding from Merck Serono. J-C. Soria: Consultancy fees from AstraZeneca, Astex, Clovis, GSK, Gammamabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, Pharmamar Pierre Fabre, Roche-Genentech, Sanofi, Servier, Symphogen, Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.